Titerverlauf

 

  • Die WHO resümiert: "There is not enough evidence to compare the antibody levels for the duration of protection with specific tetanus vaccination schedules." (WHO 2017)




Abrahamian FM. J Emerg Med. 2000 Feb;18(2):189-93.

a-t. arznei-telegramm. 2016; 47: 17-20

Bolukbasi O. Eur Neurol 1999;41(4):231-2

Borrow R. 2007. Immunological basis for immunization: Molule 3 : Tetanus (update 2006). Geneva: World Health Organization

Boyd J. Lancet 1946; 1: 113-9 

Cisse FA. Med Sante Trop. 2012 Jan-Mar;22(1):103-5.

Church JA. Pediatrcs 1985; 75:899-900

ECDC. Vaccine Schedules. (Abruf 20.02.2016)

Hammarlund E. Clin Infect Dis. 2016 May 1;62(9):1111-8. doi: 10.1093/cid/ciw066. Abruf 26.02.2017

Korger G. Klin Wochenschrift 1986; 64:767-775

Long A. Bull. U.S. Army Med. Dep. 1947; 7: 371-85 

De Melker HE. Ned Tijdschr Geneeskd 2004b, 148(9): 429-33

De Melker HE. 1999. Vaccine.18(1–2):100–108.

Newell K. Bull. World Health Organ. 1966; 35: 863-71

Pryor T. J Fam Pract. 1997 Mar;44(3):299-303.

Relyveld EH. Vaccine 1998 May-Jun;16(9-10):1016-23

Whit WG. J of Hygiene 1983; 61:283-297

WHO. 2017. WER 92:53-76.

WHO. Fact sheet Tetanus. Stand 2012(Abruf 20.02.2016)